{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06086613",
            "orgStudyIdInfo": {
                "id": "ACT22-002"
            },
            "organization": {
                "fullName": "Angitia Biopharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers",
            "officialTitle": "A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AGA2115 in Adult Healthy Volunteers",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-first-in-human-study-evaluating-in-adult-healthy-volunteers"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-10-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-11",
            "studyFirstSubmitQcDate": "2023-10-11",
            "studyFirstPostDateStruct": {
                "date": "2023-10-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Angitia Incorporated Limited",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "To understand if AGA2115 is safe and well tolerated in healthy adult volunteers."
        },
        "conditionsModule": {
            "conditions": [
                "Osteogenesis Imperfecta"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 72,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "AGA2115",
                    "type": "EXPERIMENTAL",
                    "description": "In Part A, up to 6 single ascending dose cohorts.\n\nIn Part B, up to 3 multiple ascending dose cohorts.",
                    "interventionNames": [
                        "Drug: AGA2115"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive matching placebo.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AGA2115",
                    "description": "In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort).\n\nIn Part B, participants will receive AGA2115 in multiple doses administered as a SC injection.",
                    "armGroupLabels": [
                        "AGA2115"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).\n\nIn Part B, participants will receive multiple doses of placebo administered as a SC injection.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with treatment-emergent adverse events (TEAEs)",
                    "description": "Clinically significant changes in clinical laboratory tests, vital signs, and 12-lead electrocardiograms (ECGs) will be recorded as TEAEs.",
                    "timeFrame": "Day 1 to up to end of study (approximately 85 days in Part A, approximately 169 days in Part B)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum observed concentration (Cmax) of AGA2115",
                    "timeFrame": "Day 1 to up to end of study (approximately 85 days in Part A, approximately 169 days in Part B)"
                },
                {
                    "measure": "Time to maximum observed concentration (Tmax) of AGA2115",
                    "timeFrame": "Day 1 to up to end of study (approximately 85 days in Part A, approximately 169 days in Part B)"
                },
                {
                    "measure": "Area under the concentration time curve (AUC) of AGA2115",
                    "timeFrame": "Day 1 to up to end of study (approximately 85 days in Part A, approximately 169 days in Part B)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy men and women \u226518 to \u226465 years old.\n* Vitamin D sufficiency (\u226520 ng/mL (50 nmol/L) and agree to taking Calcium and Vitamin D supplements during the trial.\n\nExclusion Criteria:\n\n* History of myocardial infarction or stroke (or other cardiovascular associated event deemed significant by investigator) within 12 months prior to Day 1.\n* Malignancy within the last 5 years (basal cell carcinoma and squamous cell carcinoma that have been excised with no recurrence within the last 5 years is allowed).\n* Hyper- or hypocalcemia.\n* Known sensitivity to mammalian-derived drug preparations and/or any biologics.\n* Pregnant or breastfeeding or planning to become pregnant (self or partner) at any time during the study.\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Elisa Dauphinee",
                    "role": "CONTACT",
                    "phone": "818-862-2068",
                    "email": "info@angitiabio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Angitia Medical Director",
                    "affiliation": "Angitia Incorporated Limited",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Orange County Research Center",
                    "status": "RECRUITING",
                    "city": "Lake Forest",
                    "state": "California",
                    "zip": "92630",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Debra Goerlitz",
                            "role": "CONTACT",
                            "phone": "714-210-6640",
                            "email": "debra.goerlitz@ocresearchcenter.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.64697,
                        "lon": -117.68922
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010013",
                    "term": "Osteogenesis Imperfecta"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010009",
                    "term": "Osteochondrodysplasias"
                },
                {
                    "id": "D000001848",
                    "term": "Bone Diseases, Developmental"
                },
                {
                    "id": "D000001847",
                    "term": "Bone Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000003095",
                    "term": "Collagen Diseases"
                },
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12936",
                    "name": "Osteogenesis Imperfecta",
                    "asFound": "Osteogenesis Imperfecta",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12932",
                    "name": "Osteochondrodysplasias",
                    "relevance": "LOW"
                },
                {
                    "id": "M12043",
                    "name": "Mucopolysaccharidosis IV",
                    "relevance": "LOW"
                },
                {
                    "id": "M5127",
                    "name": "Bone Diseases, Developmental",
                    "relevance": "LOW"
                },
                {
                    "id": "M5126",
                    "name": "Bone Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M15045",
                    "name": "Rheumatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6323",
                    "name": "Collagen Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4306",
                    "name": "Osteogenesis Imperfecta",
                    "asFound": "Osteogenesis Imperfecta",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3909",
                    "name": "Mucopolysaccharidosis Type IV",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}